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Abstract
Background: Polycystic ovary syndrome (PCOS) is challenging to diagnose. While the 2003 Rotterdam criteria are
widely used for adults, the 2018 international PCOS guideline recommended updated Rotterdam criteria with both
hyperandrogenism and oligo-anovulation for adolescents based on evidence-informed expert consensus. This study
compared the prevalence of PCOS using updated and original Rotterdam criteria in community-based adolescents
and explored long-term body mass index (BMI) trajectories across different diagnostic phenotypes.
Methods: Overall, 227 postmenarchal adolescent females from the prospective cohort Raine Study undertook
comprehensive PCOS assessment at age 14–16 years. Detailed anthropometric measurements were collected from birth
until age 22 years. Cross-sectional and longitudinal BMI were analyzed using t tests and generalized estimating equations.
Results: PCOS was diagnosed in 66 (29.1%) participants using original criteria versus 37 (16.3%) participants using
updated Rotterdam criteria. Using updated criteria, participants with PCOS had higher BMI than participants without
PCOS from prepubertal. Only the phenotype meeting the updated criteria was significantly associated with higher long-
term BMI gain whereas other PCOS phenotypes had similar BMI trajectories to participants without PCOS (p< 0.001).
Conclusions: The use of the 2018 updated Rotterdam criteria reduces over-diagnosis of PCOS in adolescents and
identifies those at the greatest risk of long-term weight gain, a key contributor to disease severity and long-term health
implications. The BMI trajectories of females with PCOS on updated criteria diverge prepubertally compared to those
without PCOS. This work supports targeting adolescents diagnosed with PCOS on the 2018 updated criteria for early
lifestyle interventions to prevent long-term health complications.
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Background
Polycystic ovary syndrome (PCOS) is the most common
endocrinopathy in women of reproductive age with an esti-
mated prevalence of 8–13% [1]. Its pathogenesis includes
insulin resistance and hyperandrogenism which drive the
reproductive (menstrual dysfunction, infertility), metabolic
(metabolic syndrome, diabetes, cardiovascular risk factors),
and psychological (anxiety, depression, low quality of life)
complications [2]. Given the high prevalence and diverse
features across the lifespan, as well as the high prevalence
of obesity which further exacerbates its clinical features,
PCOS contributes to the global burden of disease [3]. It is
therefore imperative to recognize the condition early to fa-
cilitate interventions and prevent complications.
Being a heterogeneous disorder, the diagnosis of PCOS is
difficult and often delayed [4]. PCOS diagnosis is based on
oligo-anovulation (OA), biochemical or clinical hyperandro-
genism (HA), and polycystic ovary morphology (PCOM) on
ultrasound extending across the original 1990 National In-
stitutes of Health (NIH) criteria (OA and HA) [5], the 2003
Rotterdam criteria (any two of OA, HA, and PCOM) [6],
and the Androgen Excess and Polycystic Ovary Syndrome
(AE-PCOS) Society criteria (HA and OA or PCOM or both)
[7]. The Rotterdam criteria are now widely accepted and
generate four possible diagnostic PCOS phenotypes in adult
women: (A) OA+HA+PCOM, (B) OA+HA, (C) HA+
PCOM, and (D) OA+PCOM [6]. The Rotterdam criteria
are recommended and endorsed by the 2018 international
PCOS evidence-based guideline, which was co-developed
based on unprecedented evidence synthesis and best prac-
tice methods, by world-leading multidisciplinary clinicians
and researchers across 37 societies from 71 countries, with
consumer engagement [8].
PCOS is more challenging to diagnose in adolescents,
as menstrual irregularity and multi-follicular ovaries are
part of normal pubertal physiology and the application
of adult criteria results in a high prevalence and may
over-diagnose PCOS [9, 10]. Available recommendations
on adolescent PCOS diagnostic criteria are inconsistent.
The 2018 international PCOS guideline updated the Rot-
terdam criteria and now recommends applying OA and
HA while avoiding PCOM for PCOS diagnosis in adoles-
cents [8]. However, this evidence-informed recommen-
dation was ultimately based on expert consensus with
limited evidence on the most accurate diagnostic ap-
proach in adolescents and on the natural history of
PCOS phenotypes over time. It remains unclear if the
2018 updated Rotterdam criteria capture adolescents
with PCOS who are at the greatest risk of long-term
complications and would benefit the most from lifestyle
preventative interventions [8].
Long-term weight gain is a major health concern for
women with PCOS and a key pathophysiological contribu-
tor to PCOS severity [4]. More than 60% of women with
PCOS are above healthy body mass index (BMI), exacer-
bating metabolic, reproductive, and psychological features
of PCOS [11, 12]. These effects can be ameliorated by 5–
10% weight loss, and lifestyle intervention to prevent
weight gain and promote weight loss is therefore the
cornerstone of PCOS management [8, 13]. However, exist-
ing studies examining the natural history of weight gain in
women with PCOS are limited to largely clinic-based adult
populations and women with self-reported PCOS and do
not differentiate across various PCOS diagnostic criteria or
phenotypes [14–22].
To address research priorities and evidence gaps, the
aims of the present study in an unselected adolescent
population were threefold. Firstly, we aimed to examine
the impact of the original 2003 versus the 2018 updated
Rotterdam criteria on the prevalence of PCOS diagnosis.
Secondly, we aimed to examine the natural history of
BMI trajectories in women with and without PCOS from
birth until young adulthood, applying both the original
and updated adolescent Rotterdam criteria. Thirdly, we
aimed to determine BMI trajectories across adolescent
phenotypes.
Methods
Study design and setting
The Raine Study is a prospective cohort study aiming to
investigate the influences of familial, intrauterine, peri-
natal, and environmental factors on health across the life-
span [23]. Pregnant women between 16 and 20 weeks of
gestation who attended public and private antenatal clinics
in Western Australia were recruited from 1989 to 1991.
More than 2900 pregnant women enrolled in the study
and resulted in 2868 live births [23]. To date, the cohort
has been followed up for more than 20 years with greater
than 70% of the participants still engaged in the study
[23]. Data were collected from four generations (mothers
and partners originally recruited into the study (Gen1),
Raine Study participants (Gen2), offspring of the partici-
pants (Gen3), and grandparents of the participants
(Gen0)) in the form of surveys, physical examination, and
clinical laboratory testing. Between ages 14 and 16, 723
postmenarchal Gen2 adolescent females were invited to
participate in the Menstruation in Teenagers Study which
involved the collection of self-reported menstrual diary,
urinary progesterone analysis, clinical assessment of hir-
sutism and acne, biochemical measurement of androgen
profile, and ultrasound evaluation of ovarian follicles [24].
A total of 244 Gen2 females consented to participate, and
their mean age at assessment was 15.2 years [9, 24]. All
follow-up assessments were approved by the ethics com-
mittees of King Edward Memorial Hospital and/or Prin-
cess Margaret Hospital. Further details of the Raine Study
are available at www.rainestudy.org.au.
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Outcomes
The primary outcomes of this study were PCOS preva-
lence and BMI calculated as weight in kilograms per meter
squared of height at each follow-up assessment. Partici-
pants’ anthropometric data were measured at birth and at
ages 1, 2, 3, 5, 8, 10, 14, 16, 20, and 22 by trained research
assistants using standardized protocols [25]. Anthropo-
metric data collection was limited to 600 participants of
the entire cohort at age 2 due to limitations in funding
[25]. Length or height was measured using the Harpenden
Neonatometer to the nearest 0.1 cm by two people at birth
and age 1 in a supine position [25]. From age 2 onwards,
height was measured using a Holtain stadiometer in an
anatomical position with shoes off and heels, bottom, and
head against a board [25]. Weight was measured with light
clothing (running shorts and singlet top) to the nearest
100 g using calibrated hospital scales at birth and Wedder-
burn digital chair scales from age 1 onwards [25].
Exposure
The primary exposure was PCOS with the diagnosis ascer-
tained using the original Rotterdam criteria (two out of
three clinical features) and updated Rotterdam criteria (OA
and HA) (see Table 1 for phenotypes). OA was assessed by
a combination of menstrual diary and 12-weekly urinary
progesterone metabolite PdG analyses [9, 24]. OA was de-
fined as menstrual cycle length less than 21 or more than
35 days (as the time of assessment was approximately
3 years postmenarche), or where the cycle length varied by
more than 4 days, or the urinary PdG to creatinine ratio
was less than three times baseline secretion in at least two
of the months assessed [9, 24]. Secondary causes of men-
strual irregularity such as thyroid disorders and hyperpro-
lactinemia were excluded in all participants [9, 26].
Androgen profile was measured during the early follicular
phase (days 2 to 6 of the menstrual cycle) between 15:30
and 16:30 to account for the diurnal variation of androgen
production and to fit in with the participants’ school com-
mitments [9, 24]. Total testosterone was measured using a
double-antibody radioimmunoassay (DSL-4100, Beckman,
Australia: lower limit of sensitivity 0.347 nmol/L; conver-
sion factor to conventional units divide by 0.347 for nano-
grams per deciliter, intraassay and interpatient coefficients
of variation are 6% and 15% at the 1 nmol/L concentration,
respectively); sex hormone-binding globulin (SHBG) was
measured using a non-competitive liquid-phase immunor-
adiometric assay (SHBG-IRMA kit; Orion Diagnostica, Es-
poo, Finland: lower limit of sensitivity 1.3 nmol/L,
interassay and intrapatient coefficients of variation 2.0 to
8.6% and 15.4%, respectively) [9, 24, 26]. Biochemical HA
was defined as the top 25th centile for circulating free tes-
tosterone concentrations (calculated using the Vermeulen
equation based on total testosterone and SHBG concentra-
tions, conversion factor to conventional units divide by
0.347 for picograms per deciliter) which was at least 24.45
pmol/L for this data set [9, 24, 26]. A trained nurse evalu-
ated clinical HA using the modified Ferriman-Gallwey
score of ≥ 8 to determine hirsutism [9, 24]. PCOM was de-
termined using adult criteria (defined as ≥ 1 ovary ≥ 10cm3
in volume or ≥ 12 follicles between 2 and 9mm diameter)
[27] and evaluated using transabdominal ultrasound with a
full bladder during the early follicular phase [9, 24, 26, 28].
All ultrasounds were performed by one of two experienced
gynecological ultrasonographers while the images were
evaluated by one expert radiologist. Either a 5–2-MHz
transducer (U22; Philips Medical Systems, Bothell, WA) or
a 4-MHz transducer (Voluson 730 Expert; General Electric
Milwaukee, WI) was used. The uterine and ovarian vol-
umes were estimated using the formula 0.523 × length ×
width × height of the organ [29, 30]. Antral follicles were
defined as follicles < 10mm in diameter. Follicular number
was assessed by scanning each ovary from the inner margin
to the other margin in a longitudinal cross-sectional scan-
ning plane. If a follicle ≥ 10mm was seen, the ultrasound
was repeated in the early follicular phase of the next cycle
[9, 24, 26, 28].
Covariates
Maternal antenatal information was collected by re-
searchers from maternal medical records. Age at menar-
che, education level, employment status, smoking status,
relationship status, family income, and personal income
were collected from surveys at multiple follow-up points.
Physical activity was assessed using the International
Physical Activity Questionnaire (IPAQ) [31] during age
20 and 22 follow-ups, and the subsequent metablic
equivalent (MET)-minutes per week were computed.
Energy intake (kcal) was assessed at age 14 via 3-day
food diaries with clarification through a follow-up
phone call by a dietitian [32].
Table 1 PCOS phenotypes of each comparison group
Group OA + HA + PCOM OA +HA HA + PCOM OA + PCOM OA only HA only PCOM only No features
Original PCOS (n = 66) ✓ ✓ ✓ ✓
Updated PCOS (n = 37) ✓ ✓
Original non-PCOS (n = 161) ✓ ✓ ✓ ✓
Updated non-PCOS (n = 190) ✓ ✓ ✓ ✓ ✓ ✓
HA hyperandrogenism, OA oligo-anovulation, PCOM polycystic ovary morphology, PCOS polycystic ovary syndrome
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Statistical analysis
Analyses were restricted to Gen2 participants in the
Menstruation in Teenagers Study who were not on com-
bined oral contraceptive pills and who had a complete
assessment of PCOS features. Participants’ characteris-
tics and anthropometry were cross-tabulated using
means and standard deviation (SD) or median and inter-
quartile range (IQR) for continuous variables and fre-
quencies for categorical variables. Differences between
PCOS status subgroups were assessed using independent
t test, Fisher’s exact test, Pearson χ2 test, or Mann-
Whitney test as appropriate. Cross-sectional analysis of
group-level BMI by PCOS status at each follow-up time
point was summarized using means and SD and com-
pared using independent t tests. Longitudinal analysis of
BMI was performed using generalized estimating equa-
tions (GEE) (Gaussian family, identity link, exchangeable
covariance structure) which account for between-
subjects and within-subjects’ relationships, as well as in-
complete follow-up data. BMI change over time was
assessed by including PCOS status by time or PCOS
phenotypes (non-PCOS, OA +HA, HA + PCOM, OA +
PCOM) by time as interaction terms. Covariates were
included in the multivariable GEE model if they exhib-
ited a p value of < 0.1 in the univariate model. The final
included covariates were age of menarche, family income
at age 14, and smoking and marital status at age 22.
BMI trajectories were compared between participants
with and without PCOS by their PCOS phenotypes.
Stata software version 15 (StataCorp, College Station,
TX) was used for statistical analysis.
Results
Participants characteristics and prevalence of PCOS
Of the 244 participants, 17 were excluded due to oral
contraceptive pill usage (n = 12) and incomplete PCOS
assessment (n = 5). The remaining 227 were included in
our analysis, and the dataset contained a total of 1909 an-
thropometric measurements allowing BMI calculation
from birth until age 22. The median number of anthropo-
metric measurements per participant was 9 (range 4–10).
PCOS was diagnosed in 66 participants (prevalence of
29.1%, 95% confidence interval (CI) 23.5–35.4%) using the
original Rotterdam criteria and 37 participants (prevalence
of 16.3%, 95% CI 12.0–21.7%) using the 2018 updated
Rotterdam criteria (Table 2, Table 1). Participants with
and without PCOS on both diagnostic criteria had similar
antenatal history, gestational age at delivery, birth mea-
surements, age of menarche, family income, personal in-
come, relationship status, and smoking status. While daily
energy intake at age 14 appeared similar for participants
with and without PCOS on either diagnostic criteria, par-
ticipants with PCOS based on the original Rotterdam cri-
teria were less physically active than participants without
PCOS (Table 2). The prevalence of participants in each
BMI category at age 22 among participants with and with-
out PCOS was similar using the original Rotterdam cri-
teria but different among the subgroups in the 2018
updated adolescent Rotterdam criteria (Table 2).
Cross-sectional BMI differences by diagnostic criteria
Table 3 details the participants’ mean BMI over time.
Using the original Rotterdam criteria, participants with
and without PCOS had similar BMI in childhood, but
BMI in participants with PCOS was significantly greater
than in those without PCOS from age 14 onwards (BMI
at age 14, 22.8 ± 4.4 vs 21.0 ± 3.4, p = 0.003). Using the
updated 2018 adolescent Rotterdam criteria, the diver-
gence of BMI occurred earlier where participants with
PCOS had higher BMI than participants without PCOS
from age 5 onwards (BMI at age 5, 16.3 ± 2.0 kg/m2 vs
15.6 ± 1.4 kg/m2, p = 0.013).
Longitudinal BMI change by diagnostic criteria and
phenotypes
Table 4 shows the longitudinal models of BMI change
over time stratified by PCOS status, adjusted for age of
menarche, family income at age 14, smoking status at
age 22, and marital status at age 22. Using the original
Rotterdam criteria, participants with PCOS had signifi-
cantly greater BMI increase than participants without
PCOS from age 14 onwards (Wald test for overall differ-
ences p < 0.001). However, on the updated 2018 Rotter-
dam criteria, the BMI increase was greater in PCOS
than in those without PCOS from age 10 onwards (Wald
test for overall differences p < 0.001).
To examine if the updated 2018 Rotterdam criteria iden-
tified participants at risk of higher long-term BMI gain, we
analyzed 3 PCOS phenotypes (updated Rotterdam criteria
phenotype OA+HA and two phenotypes excluded by the
updated criteria HA+ PCOM and OA+ PCOM), by time
as an interaction term in the longitudinal analysis (Table 5).
After adjusting for age of menarche, family income at age
14, smoking at age 22, and marital status at age 22, com-
pared to those without PCOS, phenotype OA+HA (up-
dated diagnostic criteria) had greater BMI increase from
age 10, whilst phenotypes HA+ PCOM and OA+ PCOM
had comparable BMI changes over time as participants
without PCOS. The adjusted predicted mean change in
BMI trajectories of each PCOS phenotype and participants
without PCOS is shown in Fig. 1.
Discussion
To the best of our knowledge, the present study is the first
community-based prospective cohort study of women
with and without well-characterized PCOS diagnostic fea-
tures assessed in adolescent years from birth until young
adulthood. Our data clearly demonstrates that in the
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adolescent population, the 2018 international guideline
updated Rotterdam criteria detected a lower prevalence of
PCOS of 16.3% compared with 29.1% using the original
Rotterdam criteria. The updated criteria also identified ad-
olescents with PCOS with rapidly increasing BMI trajec-
tory, with long-term weight gain known to increase PCOS
severity. This study also provides novel insights into PCOS
diagnostic phenotypes and important patterns of long-
term weight gain by phenotype.
PCOS diagnosis in adolescents is controversial as the
diagnostic features of OA, HA, and PCOM overlap with
normal pubertal physiology [8]. The 2018 international
PCOS guideline process involved comprehensive evidence
synthesis and reached an evidence-informed consensus
recommendation, while also highlighting evidence gaps
and research priorities. Importantly, the guideline recom-
mended that all PCOS diagnostic phenotypes should be
captured in research to clarify the long-term natural his-
tory [8]. Longitudinal studies examining the natural history
of PCOS are scarce, mainly limited to adults in clinical set-
tings and to those with self-reported PCOS or BMI status
[14–22]. An important and large population-based North-
ern Finland Birth Cohort study has reported that women
with PCOS have earlier adiposity rebound (the second rise
in BMI following a nadir in early childhood) (age 5.2 ± 1.0
vs 5.6 ± 0.9, p < 0.001) and that BMI trajectories deviate
around this age [17]. However, the Finnish cohort included
self-reported BMI, and self-reported irregular menstrual
cycles and hirsutism, or PCOS status in adulthood [17].
The Finnish study was unable to explore key research pri-
orities on the implications of the 2018 updated Rotterdam
criteria including accurate BMI trajectories or the differen-
tial BMI patterns across diagnostic phenotypes [17].
The current study examines measured BMI trajectories
in community-based adolescents with well-characterized
PCOS features from birth until young adulthood. It shows
that in adolescents, the prevalence of the original Rotter-
dam criteria including all phenotypes was 29.1%, and the
prevalence using the updated Rotterdam criteria (HA and
OA) was 16.3%, a prevalence similar to that seen in adults
of 8–13% on systematic review and 12–18% in an Austra-
lian population using the Rotterdam criteria [1, 33]. Captur-
ing 29% of adolescents under the original Rotterdam
diagnostic criteria may contribute to over-diagnosis at this
life stage, potentially causing unnecessary psychological dis-
tress and financial and treatment burden. The fear of over-
diagnosis may also limit the willingness of clinicians to
diagnose PCOS in adolescents despite clear evidence show-
ing under-diagnosis and delayed diagnosis cause significant
frustration in the PCOS community [4]. Our findings of an
adolescent prevalence that is similar to that seen in adult-
hood when applying the updated criteria may be reassuring
for both clinicians and adolescents affected by PCOS.
A key concern in excluding phenotypes HA and PCOM
and OA and PCOM in the updated 2018 diagnostic criteria
is uncertainty about their natural history and potential for






















16.86 ± 1.33 15.79 ± 1.28 15.99 ± 1.20 15.69 ± 1.53 16.74 ± 2.09 18.32 ± 3.07 21.51 ± 3.81 23.08 ± 4.23 24.11 ± 4.77 25.03 ± 5.54
Original Rotterdam criteria (kg/m2)
O-nPCOS 16.78 ± 1.33 15.67 ± 1.26 15.96 ± 1.21 15.62 ± 1.43 16.65 ± 1.97 18.15 ± 2.99 20.97 ± 3.41 22.58 ± 3.58 23.68 ± 4.28 24.24 ± 4.48
O-PCOS 17.04 ± 1.34 16.02 ± 1.33 16.07 ± 1.18 15.86 ± 1.76 16.96 ± 2.37 18.76 ± 3.24 22.82 ± 4.40 24.36 ± 5.37 25.40 ± 5.83 27.08 ± 7.31
p value 0.193 0.296 0.585 0.307 0.329 0.181 0.003 0.021 0.061 0.015
O-nPCOS
(n = 161)
154 44 119 154 153 161 161 148 145 125
O-PCOS
(n = 66)
64 23 46 63 63 64 66 59 49 48
Updated 2018 adolescent Rotterdam criteria (kg/m2)
U-nPCOS 16.81 ± 1.36 15.72 ± 1.31 15.93 ± 1.22 15.58 ± 1.41 16.58 ± 1.92 18.13 ± 2.90 21.10 ± 2.99 22.54 ± 3.59 23.58 ± 4.20 24.19 ± 4.45
U-PCOS 17.09 ± 1.13 16.12 ± 1.14 16.34 ± 1.04 16.29 ± 2.00 17.58 ± 2.70 19.35 ± 3.76 24.19 ± 4.84 25.97 ± 5.96 27.56 ± 6.58 29.79 ± 8.22
p value 0.254 0.327 0.129 0.013 0.043 0.076 0.001 0.003 0.006 0.002
U-nPCOS
(n = 190)
182 55 142 183 181 190 189 174 168 147
U-PCOS
(n = 37)
36 12 23 34 35 35 37 33 28 26
t test was used for comparisons between the groups
O-nPCOS original non-polycystic ovary syndrome group, O-PCOS original Rotterdam polycystic ovary syndrome group, U-nPCOS updated non-polycystic ovary
syndrome group, U-PCOS updated Rotterdam polycystic ovary syndrome group
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Table 4 Difference in longitudinal BMI change from baseline (age 1) stratified by PCOS diagnostic criteria
Original Rotterdam criteria
Original non-PCOS (n = 161) Original PCOS (n = 66) Difference between the groups p value*
ΔBMI 95% CI ΔBMI 95% CI ΔBMI 95% CI
Age 1 (baseline) – – – – – –
Age 2 − 1.31 − 2.14 to − 0.47 − 2.72 − 4.78 to − 0.65 − 1.47 − 3.32 to 0.37 0.117
Age 3 − 0.93 − 1.49 to − 0.37 − 1.19 − 2.63 to 0.25 − 0.27 − 1.53 to 1.00 0.680
Age 5 − 1.21 − 1.72 to − 0.69 − 1.35 − 2.68 to − 0.02 − 0.15 − 1.33 to 1.02 0.800
Age 8 − 0.18 − 0.70 to 0.34 − 0.25 − 1.57 to 1.07 − 0.08 − 1.25 to 1.09 0.895
Age 10 1.18 0.67 to 1.69 1.82 0.50 to 3.14 0.64 − 0.53 to 1.80 0.284
Age 14 4.24 3.73 to 4.75 5.83 4.52 to 7.14 1.59 0.43 to 2.75 0.007
Age 16 5.77 5.25 to 6.29 7.41 6.07 to 8.75 1.64 0.46 to 2.82 0.006
Age 20 6.85 6.33 to 7.37 7.94 6.59 to 9.29 1.10 − 0.09 to 2.29 0.070
Age 22 7.39 6.87 to 7.91 9.40 8.07 to 10.72 2.00 0.82 to 3.17 0.001
Updated 2018 adolescent Rotterdam criteria
Updated non-PCOS (n = 190) Updated PCOS (n = 37) Difference between the groups p value*
ΔBMI 95% CI ΔBMI 95% CI ΔBMI 95% CI
Age 1 (baseline) – – – – – –
Age 2 − 1.43 − 2.21 to − 0.65 − 2.57 − 5.63 to 0.49 − 1.27 − 3.43 to 0.89 0.248
Age 3 − 0.95 − 1.45 to − 0.44 − 1.86 − 4.38 to 0.67 − 0.96 − 2.68 to 0.77 0.278
Age 5 − 1.28 − 1.75 to − 0.80 − 1.02 − 3.21 to 1.17 0.23 − 1.28 to 1.73 0.770
Age 8 − 0.26 − 0.74 to 0.21 0.32 − 1.81 to 2.45 0.56 − 0.91 to 2.03 0.457
Age 10 1.14 0.67 to 1.61 2.73 0.57 to 4.89 1.55 0.07 to 3.04 0.041
Age 14 4.22 3.75 to 4.69 7.51 5.38 to 9.64 3.27 1.80 to 4.74 < 0.001
Age 16 5.70 5.22 to 6.17 9.60 7.41 to 11.79 3.86 2.35 to 5.37 < 0.001
Age 20 6.70 6.22 to 7.18 10.20 7.97 to 12.42 3.50 1.98 to 5.04 < 0.001
Age 22 7.27 6.79 to 7.74 12.17 10.01 to 14.33 4.89 3.40 to 6.39 < 0.001
Models were generated using generalized estimating equations and adjusted for age of menarche, family income at age 14, smoking status at age 22,
and marital status at age 22
*p value for the interaction term PCOS status by age
ΔBMI mean BMI change, CI confidence interval, PCOS polycystic ovary syndrome
Table 5 Difference in longitudinal BMI change from baseline (age 1) stratified by PCOS phenotype
Original non-PCOS (n = 161) OA + HA (updated PCOS) (n = 37) HA + PCOM (n = 9) OA + PCOM (n = 20)
ΔBMI 95% CI ΔBMI 95% CI p value* ΔBMI 95% CI p value# ΔBMI 95% CI p value$
Age 1 – – – – – – – – – – –
Age 2 − 1.31 − 2.14 to − 0.47 − 2.57 − 5.63 to 0.49 0.200 − 2.02 − 4.66 to 0.61 0.745 − 1.99 − 4.94 to 0.95 0.692
Age 3 − 0.93 − 1.49 to − 0.37 − 1.86 − 4.38 to 0.67 0.273 − 0.55 − 2.83 to 1.73 0.849 − 1.27 − 2.65 to 0.10 0.694
Age 5 − 1.21 − 1.72 to − 0.69 − 1.02 − 3.21 to 1.17 0.844 − 1.41 − 3.35 to 0.54 0.888 − 1.81 − 3.18 to 0.43 0.487
Age 8 − 0.18 − 0.70 to 0.34 0.32 − 1.81 to 2.45 0.531 0.37 − 1.57 to 2.31 0.704 − 1.17 − 2.57 to 0.23 0.263
Age 10 1.18 0.67 to 1.69 2.73 0.57 to 4.89 0.047 2.82 0.88 to 4.77 0.253 0.31 − 1.07 to 1.68 0.314
Age 14 4.24 3.73 to 4.75 7.51 5.38 to 9.64 < 0.001 5.69 3.75 to 7.64 0.312 3.61 2.24 to 4.99 0.471
Age 16 5.77 5.25 to 6.29 9.60 7.41 to 11.79 < 0.001 6.33 4.39 to 8.28 0.696 4.89 3.49 to 6.29 0.322
Age 20 6.85 6.33 to 7.37 10.20 7.97 to 12.42 < 0.001 6.95 5.00 to 8.89 0.946 5.41 4.01 to 6.81 0.097
Age 22 7.39 6.87 to 7.91 12.17 10.01 to 14.33 < 0.001 6.09 4.14 to 8.03 0.365 6.74 5.32 to 8.13 0.436
Models were generated using generalized estimating equations and adjusted for age of menarche, family income at age 14, smoking status at age 22, and marital
status at age 22
ΔBMI mean BMI change, CI confidence interval, HA hyperandrogenism, OA oligo-anovulation, PCOM polycystic ovary morphology, PCOS polycystic ovary syndrome
*p value for the interaction term phenotype OA + HA by age, comparing OA + HA with original non-PCOS
#p value for the interaction term phenotype HA + PCOM by age, comparing HA + PCOM with original non-PCOS
$p value for the interaction term phenotype OA + PCOM by age, comparing OA + PCOM with original non-PCOS
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preventable long-term adverse outcomes. Our study pro-
vides novel insights into the natural history of BMI trajec-
tories across PCOS diagnostic criteria and phenotypes, with
those adolescents meeting updated criteria (phenotype HA
and OA) having the greatest BMI increase over time and
the PCOM inclusive phenotypes having a similar BMI tra-
jectory to those not affected by PCOS. Weight gain is the
key contributor to PCOS severity and long-term reproduct-
ive, cardiometabolic, and psychological complications. Our
data are consistent with those from adult women suggest-
ing more severe metabolic features in women with the HA
and OA phenotypes, potentially linked to the metabolic im-
pact of HA [34]. Our study supports the international
PCOS guideline-recommended updated Rotterdam diag-
nostic criteria in adolescents and suggests that the updated
Rotterdam criteria will identify the group that clinicians
need most to target for prevention with early lifestyle inter-
vention. The mechanisms underpinning the divergence in
BMI prepubertally noted in both the Finnish cohort and
our data are unclear [17]. Other long-term implications in-
cluding infertility, diabetes, and psychological implications
may still be increased in adolescents with OA and PCOM
and HA and PCOM phenotypes, with future studies in this
cohort needed to address these gaps.
Strengths of our study include the prospective design and
unselected community-based population, increasing
generalizability. All anthropometric measurements were col-
lected in a standardized manner which reduced measurement
errors and recall bias. Multiple time points and low dropout
rates increased statistical power. Most importantly, the PCOS
phenotypes in our study population were well characterized.
The present study also has limitations. The upper limit of
HA was set at the top 25% of free testosterone in this study
population due to the lack of standardized reference range in
this age group and to accommodate the variation of the par-
ticipants’ gynecological age. This cutoff range was also previ-
ously used in other published Raine Study papers [9, 24, 26,
28]. Given the lack of standardized adolescent definition of
PCOM, our study used the latest consensus definition of
PCOM for adults at the time (≥ 1 ovary ≥ 10cm3 in volume
or ≥ 12 follicles between 2 and 9mm diameter) which was
based on a study performed with 7 MHz transvaginal ultra-
sound transducer [27, 35]. However, it is noteworthy that
definitions of PCOM change over time with advances in
ultrasound technology, and the latest 2018 PCOS guideline
now recommends using a 8-MHz transducer and the thresh-
old updated to ≥ 20 follicles between 2 and 9mm diameter
and/or an ovarian volume of ≥ 10 cm3. The assessment of
PCOM was conducted via transabdominal pelvic ultrasound
in our study because most of these girls were not yet sexually
active. We recognize that transvaginal ultrasound is more ac-
curate in measuring ovarian volume and antral follicle count;
however, this is often inappropriate in adolescents [8]. Over-
all, 91% of our population were Caucasian, limiting
generalizability to other ethnicities. The diagnostic PCOS fea-
tures were evaluated in the adolescent population, and our
Fig. 1 Predicted longitudinal BMI change over time by PCOS phenotypes
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findings do not aim to reflect diagnostic approaches
in adulthood, where ultrasound and PCOM inclusion
in the diagnostic criteria are recommended. Finally,
we do not yet know whether the adolescent pheno-
type of PCOS persisted into adulthood and the preva-
lence of infertility, diabetes, and psychological health
in this cohort.
Conclusions
In conclusion, this study addresses key evidence gaps in
PCOS literature and international research priorities,
contributing novel findings on the reduced prevalence of
PCOS using the updated Rotterdam diagnostic criteria
in the adolescent population. We provide insight into
the natural history of weight gain across PCOS diagnos-
tic criteria and phenotypes in adolescents. We show that
updated 2018 Rotterdam criteria requiring both HA and
OA identify adolescents most at risk of excess weight
gain as a key driver of PCOS severity, a group who
should be targeted for early lifestyle intervention and
prevention. Our findings support the 2018 international
PCOS guideline’s updated Rotterdam diagnostic criteria
and the omission of sonographic PCOM evaluation for
adolescent PCOS diagnosis [8]. The use of the updated
Rotterdam criteria may limit over-diagnosis of PCOS in
adolescents, increase clinician confidence in accurate
diagnosis in adolescents, and limit reciprocal under-
diagnosis, currently rife in PCOS. Whilst the long-term
natural history of clinical outcomes is yet to be eluci-
dated, the 2018 international guideline recommends that
adolescents who do not fulfill the updated Rotterdam
criteria and have persistent oligo-anovulation or hyper-
androgenism can be considered at risk for PCOS and be
reassessed in adulthood.
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